Ehteshami Maryam, Tao Sijia, Zandi Keivan, Hsiao Hui-Mien, Jiang Yong, Hammond Emily, Amblard Franck, Russell Olivia O, Merits Andres, Schinazi Raymond F
Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Tropical Infectious Disease Research and Education Center (TIDREC), Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02395-16. Print 2017 Apr.
Chikungunya virus (CHIKV) represents a reemerging global threat to human health. Recent outbreaks across Asia, Europe, Africa, and the Caribbean have prompted renewed scientific interest in this mosquito-borne alphavirus. There are currently no vaccines against CHIKV, and treatment has been limited to nonspecific antiviral agents, with suboptimal outcomes. Herein, we have identified β-d--hydroxycytidine (NHC) as a novel inhibitor of CHIKV. NHC behaves as a pyrimidine ribonucleoside and selectively inhibits CHIKV replication in cell culture.
基孔肯雅病毒（CHIKV）对人类健康构成了新出现的全球威胁。最近在亚洲、欧洲、非洲和加勒比地区爆发的疫情引发了科学界对这种蚊媒甲病毒的新关注。目前尚无针对CHIKV的疫苗，治疗仅限于非特异性抗病毒药物，效果欠佳。在此，我们已确定β-D-羟基胞苷（NHC）是一种新型的CHIKV抑制剂。NHC表现为嘧啶核糖核苷，并在细胞培养中选择性抑制CHIKV复制。
